Tags: revenue, dupixent, immunology

Sanofi and Regeneron Report Dupixent Tops $17.8B in 2025 Annual Revenue

By FieldPulse Editorial · March 12, 2026

A high-signal Sanofi/Regeneron immunology story about franchise scale, access strength, and what continued Dupixent growth means in the field.

Sanofi and Regeneron reported that Dupixent (dupilumab) achieved approximately $17.8 billion in global net sales for full-year 2025, establishing a new record for the IL-4/IL-13 inhibitor and cementing its position as the world's best-selling immunology drug.

The 2025 result represents approximately 26% growth year-over-year, driven by continued uptake in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, prurigo nodularis, and eosinophilic esophagitis.

The companies guided to $20–23 billion by 2028, contingent on continued label expansions and new indication approvals.

For reps in the field, formulary access in commercial lives has remained strong, though Medicare Part D remains a more complex conversation.

Biosimilar dupilumab timelines remain a topic of internal discussion, with management reiterating that the data package and IP position provide a long runway.